Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/36/3397/4983962 by Ed 'DeepDyve' Gillespie user on 18 October 2018 DISCUSSION FORUM European Heart Journal (2018) 39, 3397 doi:10.1093/eurheartj/ehy241 Javier Bermejo*, Raquel Yotti, and Francisco Ferna´ndez-Avile´s; on behalf of the SIOVAC Investigators Hospital General Universitario Gregorio Mara~ no´n, Instituto de Investigacio´n Sanitaria Gregorio Mara~ no´n, Facultad de Medicina, Universidad Complutense de Madrid, and CIBERCV, Dr Esquerdo 46, 28007 Madrid, Spain Online publish-ahead-of-print 24 April 2018 This commentary refers to ‘The elephant in the room’, by . or TAPSE. Thus, evidence from randomized clinical trials supports H. Al Maluli on page 3396. . avoiding pulmonary vasodilators in Group 2 PH, irrespective of the degree of RV dysfunction or RV-PA uncoupling. We read with interest the letter of Dr Al Maluli, and very much . In patients enrolled in the SIOVAC trial, despite normal prosthetic appreciate his interest on our work. We agree that right ventricular . valve function and diuretic optimization, pulmonary capillary wedge (RV) function has a central role in patients with pulmonary hyper- pressure was unexpectedly high. Elevated left atrial pressure arises as tension (PH) and should never been overlooked. In fact, the the major determinant of an abnormal pulmonary circulation and out- . 3 SIOVAC trial included a comprehensive assessment of RV structure . comesinthispopulation. Therefore, we believe our results call for and function using echocardiography and, in a small group of patients, . redirecting research efforts towards understanding, preventing, and magnetic resonance. . eventually treating residual post-capillary PH in patients with valvular Dr Al Maluli suggests that clinical trials with pulmonary vasodila- heart disease (VHD). tors for Group 2 PH should target exclusively patients with overt . Conflict of interest: none declared. signs of RV dysfunction. Although no clinical trial has been designed in such a way, ancillary data from randomized clinical trials do not an- . References ticipate a favourable effect of sildenafil in this subset of patients. 1. Bermejo J, Yotti R, Garcia-Orta R, Sanchez-Fernandez PL, Castano M, Segovia- The RELAX trial showed a neutral effect of sildenafil compared to Cubero J, Escribano-Subias P, San Roman JA, Borras X, Alonso-Gomez A, Botas J, placebo on peak oxygen consumption at 6 months. Importantly, a Crespo-Leiro MG, Velasco S, Bayes-Genis A, Lopez A, Munoz-Aguilera R, de Teresa specific interaction analysis failed to identify any benefit of sildenafil E, Gonzalez-Juanatey JR, Evangelista A, Mombiela T, Gonzalez-Mansilla A, Elizaga J, . Martin-Moreiras J, Gonzalez-Santos JM, Moreno-Escobar E, Fernandez-Aviles F; neither in patients with RV dysfunction nor with RV-pulmonary Sildenafil for Improving Outcomes after VAlvular Correction (SIOVAC) Investigators. artery (PA) uncoupling at enrolment. Sildenafil for improving outcomes in patients with corrected valvular heart disease Patients with RV dysfunction and combined pre and post-capillary . and persistent pulmonary hypertension: a multicenter, double-blind, randomized clin- ical trial. Eur Heart J 2018;39:1255–1264. PH were also represented in the SIOVAC trial. In fact, 57% of 2. Hussain I, Mohammed SF, Forfia PR, Lewis GD, Borlaug BA, Gallup DS, Redfield patients had PVR > 3 WU, 50% had tricuspid annular plane systolic . MM. Impaired right ventricular-pulmonary arterial coupling and effect of sildenafil excursion (TAPSE) < 15 mm, and 29% significant tricuspid regurgita- . in heart failure with preserved ejection fraction: an ancillary analysis from the 1 . Phosphodiesterase-5 Inhibition to Improve Clinical Status And Exercise Capacity tion. Although we pre-defined a searching strategy for drug res- . in Diastolic Heart Failure (RELAX) trial. Circ Heart Fail 2016;9:e002729. ponders, all interaction analyses were non-significant. Observed . 3. Galie N, Manes A, Dardi F, Palazzini M. Aiming at the appropriate target for the trends did not point towards a favourable effect of sildenafil in . treatment of pulmonary hypertension due to left heart disease. Eur Heart J 2018; patients with higher values of PVR, or lower values of cardiac index . 39:1265–1268. * Corresponding author. Tel: þ34 91 5868279, Fax: þ34 91 5866727, Email: email@example.com Published on behalf of the European Society of Cardiology. All rights reserved. V The Author(s) 2018. For permissions, please email: firstname.lastname@example.org.
European Heart Journal – Oxford University Press
Published: Sep 21, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera